Teva director sells 415 shares at $37.25

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) director Ronit Satchi-Fainaro reported selling 415 Ordinary Shares on August 21, 2026 at a price of $37.25 per share in an open-market or private transaction.

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) director Ronit Satchi-Fainaro reported selling 415 Ordinary Shares on August 21, 2026 at a price of $37.25 per share in an open-market or private transaction. Following this sale, the director directly holds 111,986 Ordinary Shares, which may be represented by American Depositary Shares, each currently representing one Ordinary Share.

Insider Trade Summary

Net Seller: 415 shares

Net Sell 1 txn

Insider Satchi-Fainaro Ronit

Role Director

Sold 415 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1	415	$37.25	$15K

Holdings After Transaction: Ordinary Shares — 111,986 shares (Direct)

Footnotes (1)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Key Figures

Shares sold: 415 Ordinary Shares Sale price per share: $37.25 per share Shares held after transaction: 111,986 Ordinary Shares +1 more

4 metrics

Shares sold 415 Ordinary Shares Non-derivative sale on August 21, 2026

Sale price per share $37.25 per share Ordinary Shares sale on August 21, 2026

Shares held after transaction 111,986 Ordinary Shares Direct holdings of Ronit Satchi-Fainaro following the sale

ADS to Ordinary Share ratio 1 ADS : 1 Ordinary Share Each American Depositary Share currently represents one Ordinary Share

Key Terms

Ordinary Shares, American Depositary Shares

2 terms

Ordinary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA director Ronit Satchi-Fainaro report?

Ronit Satchi-Fainaro reported a sale of 415 Ordinary Shares of TEVA on August 21, 2026 in an open-market or private transaction at $37.25 per share.

How many TEVA shares did Ronit Satchi-Fainaro sell and at what price?

Ronit Satchi-Fainaro sold 415 Ordinary Shares of TEVA at a price of $37.25 per share on August 21, 2026.

What are Ronit Satchi-Fainaro’s TEVA holdings after this Form 4 transaction?

After the reported sale, Ronit Satchi-Fainaro directly holds 111,986 Ordinary Shares of TEVA, according to the Form 4 filing.

Are TEVA’s Ordinary Shares in this filing linked to American Depositary Shares (ADS)?

Yes. A footnote states that the Ordinary Shares may be represented by American Depositary Shares, and that each ADS currently represents one Ordinary Share.

Was the TEVA insider sale made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote indicating that the 415-share sale on August 21, 2026 was made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:03 PM EDT Accepted by SEC EDGAR 08/25/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Satchi-Fainaro Ronit

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	08/21/2026		S		415	D	$37.25	111,986	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Ronit Satchi-Fainaro	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)